Intermediate Risk MDS with Dr. Swapna Thota
What does the diagnosis, Intermediate-Risk MDS mean? Learn from Myelodysplastic Syndromes expert, Dr. Swapna Thota, in this recording.
Diagnosing MDS, with Dr. Joshua Zeidner
Dr. Joshua Zeidner explains why it is critical for patients to receive an accurate diagnosis for MDS, or Myelodysplastic Syndromes. He describes the steps to determine the presence of the disease, and also discusses some of the treatments available.
Blood Clots in Patients with PNH, with Dr. Maxim Norkin
Dr. Norkin explains why and how patients with PNH can develop blood clots, as well as prevention and treatment.
Treating AML in Older Adults, with Dr. Timothy Pardee
Dr. Timothy Pardee discusses treatments for AML, or Acute Myeloid Leukemia, occurring in older adults.
Advances in Treating PNH (Paroxysmal Nocturnal Hemoglobinuria) with Dr. Allyson Pishko - 2022
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria.
Transplant for Older Patients with Dr. Nandita Khera - 2022
Dr. Nandita Khera discusses why and when transplants can be recommended for older patients in this podcast episode.
Treatment Options for MDS (Myelodysplastic Syndromes) with Dr. Rory Shallis - 2022
Dr. Rory Shallis discusses a variety of current treatments for MDS, or Myelodysplastic Syndromes
Treating MDS after Hypomenthylating Failure with Dr. Jacqueline Garcia - 2022
Dr. Jacqueline Garcia discusses the use of hypomenthylating agents.
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Key Points
Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD.
Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids.